Press coverage about IsoRay (NASDAQ:ISR) has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IsoRay earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.6205710006634 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Separately, HC Wainwright reissued a “neutral” rating on shares of IsoRay in a research note on Monday, August 20th.

Shares of NASDAQ ISR opened at $0.53 on Wednesday. IsoRay has a 52-week low of $0.36 and a 52-week high of $1.22.

IsoRay Company Profile

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Recommended Story: What is a Fiduciary?

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.